Nasdaq
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases
German cancer antibody biotech eyes SPAC as route to Nasdaq
Veraxa, Antibodies, SPAC, German language, Nasdaq
Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing
Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment
Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce
biotech closure, oncology company, financial troubles, workforce termination, wind-down operations, Nasdaq delisting, strategic alternatives
Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments
Sionna Therapeutics, IPO, cystic fibrosis, CFTR protein, NBD1 stabilizers, biotech, Nasdaq, clinical trials
Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs
Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding
Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch
Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development
Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4
Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases
Ceribell Pursues $101M Nasdaq IPO for Revolutionary Seizure-Spotting Headset
Ceribell, Seizure-Spotting Headset, Nasdaq IPO, Emergency Seizure Care, Brain-Reading Technology
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering